A Trial to Compare BioChaperone Insulin Lispro Formulations With US Approved Humalog® and With EU Approved Humalog® in Patients With Type 1 Diabetes Mellitus

NCT04501107 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 1 Diabetes

Interventions

DRUG: Administration of BioChaperone insulin lispro reconstituted with Humalog® (IMP1)
DRUG: Administration of Ready-to-use BioChaperone insulin lispro (IMP2)
DRUG: Administration of US-approved Humalog® (IMP3)
DRUG: Administration of EU-approved Humalog® (IMP4)

Sponsor

Adocia